François Mach

List of Publications by Year
in descending order

169 papers	26,653 citations	66343 42 h-index	7160 153 g-index
172 all docs	172 docs citations	172 times ranked	32657 citing authors

#	Article	IF	Citations
1	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. Nicotine and Tobacco Research, 2023, 25, 58-65.	2.6	2
2	Combination lipid-lowering therapy as first-line strategy in very high-risk patients. European Heart Journal, 2022, 43, 830-833.	2.2	92
3	Current perceptions and practices in lipid management: results of a European Society of Cardiology/European Atherosclerosis Society Survey. European Journal of Preventive Cardiology, 2022, 28, 2030-2037.	1.8	8
4	PCSK9 Inhibition could be Effective for Acute Myocardial Infarction. Current Medicinal Chemistry, 2022, 29, 1016-1026.	2.4	3
5	Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. Cardiovascular Research, 2022, 118, 2367-2384.	3.8	45
6	European Society of Cardiology Quality Indicators for Cardiovascular Disease Prevention: developed by the Working Group for Cardiovascular Disease Prevention Quality Indicators in collaboration with the European Association for Preventive Cardiology of the European Society of Cardiology. European Journal of Preventive Cardiology, 2022, 29, 1060-1071.	1.8	25
7	The â€˜ten commandmentsâ€™ for the 2021 ESC Guidelines on CVD prevention. European Heart Journal, 2022, 43, 174-176.	2.2	4
8	Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study. Advances in Therapy, 2022, 39, 504-517.	2.9	8
9	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. American Heart Journal, 2022, 247, 33-41.	2.7	8
10	Single-Cell RNA-Seq Reveals a Crosstalk between Hyaluronan Receptor LYVE-1-Expressing Macrophages and Vascular Smooth Muscle Cells. Cells, 2022, 11, 411.	4.1	11
11	Single-Cell Analysis Uncovers Osteoblast Factor Growth Differentiation Factor 10 as Mediator of Vascular Smooth Muscle Cell Phenotypic Modulation Associated with Plaque Rupture in Human Carotid Artery Disease. International Journal of Molecular Sciences, 2022, 23, 1796.	4.1	11
12	NLRP3 Inflammasome Activation Controls Vascular Smooth Muscle Cells Phenotypic Switch in Atherosclerosis. International Journal of Molecular Sciences, 2022, 23, 340.	4.1	40
13	Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts premature death in acute coronary syndromes. European Heart Journal, 2022, 43, 1849-1860.	2.2	28
14	A Short Intervention and an Interactive e-Learning Module to Motivate Medical and Dental Students to Enlist as First Responders: Implementation Study. Journal of Medical Internet Research, 2022, 24, e38508.	4.3	6
15	Follicular regulatory helper T cells control the response of regulatory B cells to a high-cholesterol diet. Cardiovascular Research, 2021, 117, 743-755.	3.8	13
16	Prognostic value of total testosterone levels in patients with acute coronary syndromes. European Journal of Preventive Cardiology, 2021, 28, 235-242.	1.8	7
17	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. European Journal of Preventive Cardiology, 2021, 28, 59-65.	1.8	30
18	Cardiovascular risk and testosterone â€“ from subclinical atherosclerosis to lipoprotein function to heart failure. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 257-274.	5.7	26

#	Article	IF	Citations
19	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. Atherosclerosis, 2021, 319, 51-61.	0.8	37
20	Air pollution triggers inflammation and cardiovascular events: now is the time to act. European Heart Journal, 2021, 42, 773-775.	2.2	9
21	Improving 1-year mortality prediction in ACS patients using machine learning. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 855-865.	1.0	9
22	Reduced adrenal stress response in patients on PCSK9 inhibitor therapy. Atherosclerosis, 2021, 325, 63-68.	0.8	3
23	2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal, 2021, 42, 3227-3337.	2.2	2,517
24	Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging studyâ€"Rationale and design of the PACMAN-AMI trial. American Heart Journal, 2021, 238, 33-44.	2.7	17
25	Prognosis of Laboratory-Confirmed Influenza and Respiratory Syncytial Virus in Acute Heart Failure. Journal of Clinical Medicine, 2021, 10, 4546.	2.4	1
26	It's never too early to beat your low-density lipoprotein cholesterol. Archives of Cardiovascular Diseases, 2021, 114, 1-3.	1.6	1
27	Cysteineâ€Rich Angiogenic Inducer 61 Improves Prognostic Accuracy of GRACE (Global Registry of Acute) Tj ETQq1 1 0.784314 rgBT Heart Association, 2021, 10, e020488.	3.7	4
28	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. Preventive Medicine Reports, 2021, 24, 101583.	1.8	0
29	Symptoms and quality of life at 1-year follow up of patients discharged after an acute COVID-19 episode. Swiss Medical Weekly, 2021, 151, w30093.	1.6	14
30	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 589-598.	1.0	7
31	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 2020, 41, 111-188.	2.2	4,871
32	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
33	Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. Drugs, 2020, 80, 229-239.	10.9	21
34	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. Thrombosis and Haemostasis, 2020, 120, 168-180.	3.4	13
35	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	1.7	1
36	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. International Journal of Cardiology, 2020, 303, 8-13.	1.7	5

#	Article	IF	Citations
37	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2020, 13, 618-628.	2.4	8
38	Atherosclerotic plaque vulnerability is increased in mouse model of lupus. Scientific Reports, 2020, 10, 18324.	3.3	8
39	Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia. New England Journal of Medicine, 2020, 383, 1317-1327.	27.0	108
40	Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial. Trials, 2020, 21, 770.	1.6	34
41	Anti-Apolipoprotein A-1 IgG Influences Neutrophil Extracellular Trap Content at Distinct Regions of Human Carotid Plaques. International Journal of Molecular Sciences, 2020, 21, 7721.	4.1	8
42	An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial. JAMA Cardiology, 2020, 5, 709.	6.1	63
43	Cognition After Lowering LDL-Cholesterol With Evolocumab. Journal of the American College of Cardiology, 2020, 75, 2283-2293.	2.8	62
44	Optimal Timing of Invasive Coronary Angiography following NSTEMI. Journal of Interventional Cardiology, 2020, 2020, 1-9.	1.2	6
45	Platelet-to-lymphocyte ratio at the time of carotid endarterectomy is associated with acute coronary syndrome occurrence. Journal of Cardiovascular Medicine, 2020, 21, 80-82.	1.5	8
46	Cardiotrophin-1 Deficiency Abrogates Atherosclerosis Progression. Scientific Reports, 2020, 10, 5791.	3.3	9
47	Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction. JAMA Cardiology, 2020, 5, 952.	6.1	56
48	Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project. Atherosclerosis Supplements, 2020, 42, e49-e58.	1.2	23
49	2019 ESC/EAS Guidelines for themanagement of dyslipidaemias: lipid modification to reduce cardiovascular risk. Russian Journal of Cardiology, 2020, 25, 3826.	1.4	199
50	A Short Intervention Followed by an Interactive E-Learning Module to Motivate Medical Students to Enlist as First Responders: Protocol for a Prospective Implementation Study. JMIR Research Protocols, 2020, 9, e24664.	1.0	8
51	Impact of the COVID-19 pandemic on acute coronary syndromes. Swiss Medical Weekly, 2020, 150, w20448.	1.6	27
52	Intravascular lithotripsy to treat an ostial left main coronary artery stenosis due to porcelain aorta in a patient with congenital HDL deficiency. Anatolian Journal of Cardiology, 2020, 24, 345-346.	0.9	1
53	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. Journal of Clinical Medicine, 2019, 8, 1002.	2.4	11
54	Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure. Journal of Clinical Medicine, 2019, 8, 1684.	2.4	5

#	Article	IF	Citations
55	Relationship between HDL Cholesterol Efflux Capacity, Calcium Coronary Artery Content, and Antibodies against ApolipoproteinA-1 in Obese and Healthy Subjects. Journal of Clinical Medicine, 2019, 8, 1225.	2.4	13
56	Gender Specificity and Interpretation of Functional Cardiac Imaging: Let's Talk about Sex. Thrombosis and Haemostasis, 2019, 119, 1379-1381.	3.4	2
57	Evolocumab for Early Reduction of LDLÂCholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). Journal of the American College of Cardiology, 2019, 74, 2452-2462.	2.8	135
58	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. European Heart Journal, 2019, 40, 2700-2709.	2.2	79
59	Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naÃ¯ve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort. Atherosclerosis, 2019, 284, 253-259.	0.8	9
60	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. PLoS ONE, 2019, 14, e0211464.	2.5	6
61	Inflammation during acute coronary syndromes â€" Risk of cardiovascular events and bleeding. International Journal of Cardiology, 2019, 287, 13-18.	1.7	22
62	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2019, 49, e13117.	3.4	24
63	Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation. Journal of Clinical Medicine, 2019, 8, 2035.	2.4	10
64	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation, 2019, 139, 1483-1492.	1.6	533
65	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. Swiss Medical Weekly, 2019, 149, w20049.	1.6	1
66	Determinants of hospital length of stay after transcatheter aortic valve implantation with self-expanding prostheses: a prospective, single centre observational study. Swiss Medical Weekly, 2019, 149, w20095.	1.6	2
67	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	11
68	The quest for endothelial atypical cannabinoid receptor: BKCa channels act as cellular sensors for cannabinoids in in vitro and in situ endothelial cells. Vascular Pharmacology, 2018, 102, 44-55.	2.1	18
69	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. Cardiovascular Research, 2018, 114, 1178-1188.	3.8	44
70	Apelinâ€13 treatment enhances the stability of atherosclerotic plaques. European Journal of Clinical Investigation, 2018, 48, e12891.	3.4	24
71	So lowâ€¦ so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. European Heart Journal, 2018, 39, 382-384.	2.2	4
72	Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis. International Journal of Cardiology, 2018, 255, 195-199.	1.7	40

#	Article	IF	Citations
73	Serum lipoprotein (a) predicts acute coronary syndromes in patients with severe carotid stenosis. European Journal of Clinical Investigation, 2018, 48, e12888.	3.4	13
74	Ca2+-dependent potassium channels and cannabinoid signaling in the endothelium of apolipoprotein E knockout mice before plaque formation. Journal of Molecular and Cellular Cardiology, 2018, 115, 54-63.	1.9	8
75	Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis. Vascular Pharmacology, 2018, 102, 37-43.	2.1	21
76	Adverse effects of statin therapy: perception vs. the evidence â€" focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal, 2018, 39, 2526-2539.	2.2	262
77	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 129-138.	1.0	70
78	Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. European Heart Journal, 2018, 39, 1172-1180.	2.2	150
79	Impact of long distance rowing on biological health: A pilot study. Clinical Biochemistry, 2018, 52, 142-147.	1.9	7
80	Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?. European Heart Journal, 2018, 39, 4109-4111.	2.2	44
81	Design of the randomized, placeboâ€controlled evolocumab for early reduction of LDLâ€cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clinical Cardiology, 2018, 41, 1513-1520.	1.8	20
82	Prognostic Value of SYNTAX Score II in Patients with Acute Coronary Syndromes Referred for Invasive Management: A Subanalysis from the SPUM and COMFORTABLE AMI Cohorts. Cardiology Research and Practice, 2018, 2018, 1-11.	1.1	9
83	Biomarkers and arrhythmia recurrence following radiofrequency ablation of atrial fibrillation. Journal of International Medical Research, 2018, 46, 5183-5194.	1.0	14
84	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. PLoS ONE, 2018, 13, e0195174.	2.5	21
85	Lipid management in ACS: Should we go lower faster?. Atherosclerosis, 2018, 275, 368-375.	0.8	27
86	Resistin exerts a beneficial role in atherosclerotic plaque inflammation by inhibiting neutrophil migration. International Journal of Cardiology, 2018, 272, 13-19.	1.7	25
87	Differential Association of Cx37 and Cx40 Genetic Variants in Atrial Fibrillation with and without Underlying Structural Heart Disease. International Journal of Molecular Sciences, 2018, 19, 295.	4.1	15
88	Serum cardiovascular risk biomarkers in preâ€pubertal obese children. European Journal of Clinical Investigation, 2018, 48, e12995.	3.4	7
89	Lipoprotein(a): the perpetual supporting actor. European Heart Journal, 2018, 39, 2597-2599.	2.2	11
90	Prognostic value of pulse pressure after an acute coronary syndrome. Atherosclerosis, 2018, 277, 219-226.	0.8	15

#	Article	IF	Citations
91	Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis. International Journal of Cardiology, 2018, 263, 138-141.	1.7	20
92	Follicular regulatory T cell in atherosclerosis. Journal of Leukocyte Biology, 2018, 104, 925-930.	3.3	15
93	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. Journal of Infection, 2018, 76, 186-195.	3.3	12
94	The fear of dying and occurrence of posttraumatic stress symptoms after an acute coronary syndrome: A prospective observational study. Journal of Health Psychology, 2017, 22, 208-217.	2.3	14
95	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. European Heart Journal, 2017, 38, ehw582.	2.2	317
96	GPR55 agonist lysophosphatidylinositol and lysophosphatidylcholine inhibit endothelial cell hyperpolarization via GPR-independent suppression of Na+-Ca2+ exchanger and endoplasmic reticulum Ca2+ refilling. Vascular Pharmacology, 2017, 89, 39-48.	2.1	14
97	Design and rationale of the <scp>EBBINGHAUS</scp> trial: A phase 3, doubleâ€blind, placeboâ€controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipidâ€lowering therapyâ€"A cognitive study of patients enrolled in the <scp>FOURIER</scp> trial. Clinical Cardiology, 2017, 40, 59-65.	1.8	54
98	Direct activation of Ca2+ and voltage-gated potassium channels of large conductance by anandamide in endothelial cells does not support the presence of endothelial atypical cannabinoid receptor. European Journal of Pharmacology, 2017, 805, 14-24.	3.5	13
99	Lipoprotein(a): the revenant. European Heart Journal, 2017, 38, 1553-1560.	2.2	133
100	Alamandine abrogates neutrophil degranulation in atherosclerotic mice. European Journal of Clinical Investigation, 2017, 47, 117-128.	3.4	15
101	Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International) Tj ETQq1 1 0.784314 rgBT /Overlock		32
102	Cognitive Function in a Randomized Trial of Evolocumab. New England Journal of Medicine, 2017, 377, 633-643.	27.0	366
103	4D cardiac imaging at clinical 3.0 T provides accurate assessment of murine myocardial function and viability. Magnetic Resonance Imaging, 2017, 44, 46-54.	1.8	1
104	Impact of CD14 Polymorphisms on Anti-Apolipoprotein A-1 IgG-Related Coronary Artery Disease Prediction in the General Population. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2342-2349.	2.4	27
105	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	29
106	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. European Heart Journal, 2017, 38, 3493-3502.	2.2	46
107	Anti-Apolipoprotein A-1 IgG Predict All-Cause Mortality and Are Associated with Fc Receptor-Like 3 Polymorphisms. Frontiers in Immunology, 2017, 8, 437.	4.8	30
108	Myeloid IL-10 receptor signalling as pro-atherogenic factor modulating cholesterol homeostasis. Thrombosis and Haemostasis, 2016, 116, 407-407.	3.4	0

#	Article	IF	Citations
109	Early Discharge in Low-Risk Patients Hospitalized for Acute Coronary Syndromes: Feasibility, Safety and Reasons for Prolonged Length of Stay. PLoS ONE, 2016, 11, e0161493.	2.5	13
110	Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis. Mediators of Inflammation, 2016, 2016, 1-10.	3.0	17
111	Health utility indexes in patients with acute coronary syndromes. Open Heart, 2016, 3, e000419.	2.3	14
112	Treatment with anti-RANKL antibody reduces infarct size and attenuates dysfunction impacting on neutrophil-mediated injury. Journal of Molecular and Cellular Cardiology, 2016, 94, 82-94.	1.9	41
113	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European Heart Journal, 2016, 37, 1967-1976.	2.2	433
114	Antiâ€ApoAâ€1 IgG serum levels predict worse poststroke outcomes. European Journal of Clinical Investigation, 2016, 46, 805-817.	3.4	17
115	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. Circulation, 2016, 134, 698-709.	1.6	99
116	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. European Journal of Internal Medicine, 2016, 35, 83-88.	2.2	1
117	Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages. Vascular Pharmacology, 2016, 85, 57-65.	2.1	20
118	The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. Nature Genetics, 2016, 48, 1171-1184.	21.4	362
119	Decreased serum <scp>PCSK</scp>9 levels after ischaemic stroke predict worse outcomes. European Journal of Clinical Investigation, 2016, 46, 1053-1062.	3.4	9
120	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre beforeâ€"after study with parallel group comparisons. BMJ Open, 2016, 6, e011520.	1.9	18
121	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. European Heart Journal, 2016, 37, 546-553.	2.2	120
122	Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?. European Heart Journal, 2016, 37, 3569-3575.	2.2	30
123	Sphingosine-1-phosphate reduces ischaemiaâ€"reperfusion injury by phosphorylating the gap junction protein Connexin43. Cardiovascular Research, 2016, 109, 385-396.	3.8	55
124	Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. Swiss Medical Weekly, 2016, 146, w14275.	1.6	2
125	New concepts in the management of dyslipidaemiaa. Swiss Medical Weekly, 2016, 146, w14378.	1.6	0
126	Leptin/adiponectin ratio predicts poststroke neurological outcome. European Journal of Clinical Investigation, 2015, 45, 1184-1191.	3.4	20

#	Article	IF	Citations
127	Stairs instead of elevators at the workplace decreases <scp>PCSK</scp>9 levels in a healthy population. European Journal of Clinical Investigation, 2015, 45, 1017-1024.	3.4	34
128	Improving Reconstituted HDL Composition for Efficient Post-Ischemic Reduction of Ischemia Reperfusion Injury. PLoS ONE, 2015, 10, e0119664.	2.5	40
129	The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the C-Terminal Helix: A New Rationale for Diagnosis and Treatment of Cardiovascular Disease?. PLoS ONE, 2015, 10, e0132780.	2.5	26
130	Statin-associated muscle symptoms: impact on statin therapyâ€"European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal, 2015, 36, 1012-1022.	2.2	1,024
131	Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways. Vascular Pharmacology, 2015, 64, 16-27.	2.1	42
132	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. European Journal of Internal Medicine, 2015, 26, 56-62.	2.2	37
133	New genetic loci link adipose and insulin biology to body fat distribution. Nature, 2015, 518, 187-196.	27.8	1,328
134	Genetic studies of body mass index yield new insights for obesity biology. Nature, 2015, 518, 197-206.	27.8	3,823
135	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis, 2015, 239, 118-124.	0.8	26
136	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal, 2015, 36, 2438-2445.	2.2	129
137	Sweet<i>less</i>'n low LDL-C targets for PCSK9 treatment : FigureÂ1. European Heart Journal, 2015, 36, 1146-1148.	2.2	10
138	Treatment with sulphated galactan inhibits macrophage chemotaxis and reduces intraplaque macrophage content in atherosclerotic mice. Vascular Pharmacology, 2015, 71, 84-92.	2.1	7
139	PCSK9 inhibitors. Swiss Medical Weekly, 2015, 145, w14094.	1.6	13
140	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart, 2015, 101, 854-863.	2.9	38
141	Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke. European Journal of Clinical Investigation, 2015, 45, 579-586.	3.4	40
142	Treatment with KLEPTOSEÂ® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response. Vascular Pharmacology, 2015, 72, 197-208.	2.1	14
143	Diminazene enhances stability of atherosclerotic plaques in ApoE-deficient mice. Vascular Pharmacology, 2015, 74, 103-113.	2.1	20
144	Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. European Heart Journal, 2015, 36, 516-526.	2.2	37

#	Article	IF	Citations
145	Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2. Antioxidants and Redox Signaling, 2015, 23, 460-489.	5.4	56
146	Use and role of monoclonal antibodies and other biologics in preventive cardiology. Swiss Medical Weekly, 2015, 145, w14179.	1.6	3
147	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. PLoS ONE, 2014, 9, e93147.	2.5	28
148	Statin Treatment Is Associated with Reduction in Serum Levels of Receptor Activator of NF-<i>Î°</i>B Ligand and Neutrophil Activation in Patients with Severe Carotid Stenosis. Mediators of Inflammation, 2014, 2014, 1-11.	3.0	26
149	Advanced Glycation End Products Play Adverse Proinflammatory Activities in Osteoporosis. Mediators of Inflammation, 2014, 2014, 1-9.	3.0	82
150	Implementation strategies of Systems Medicine in clinical research and home care for cardiovascular disease patients. European Journal of Internal Medicine, 2014, 25, 785-794.	2.2	9
151	Recombinant Tissue Plasminogen Activator Enhances Microglial Cell Recruitment after Stroke in Mice. Journal of Cerebral Blood Flow and Metabolism, 2014, 34, 802-812.	4.3	31
152	A9.11â€¦Anti-apolipoprotein A1 autoantibodies induce tissue factor activity and expression: a role in atherothrombosis. Annals of the Rheumatic Diseases, 2014, 73, A96.1-A96.	0.9	0
153	Discovery and refinement of loci associated with lipid levels. Nature Genetics, 2013, 45, 1274-1283.	21.4	2,641
154	An Emerging Role of Glucagon-Like Peptide-1 in Preventing Advanced-Glycation-End-Product-Mediated Damages in Diabetes. Mediators of Inflammation, 2013, 2013, 1-9.	3.0	20
155	Inflammation Is a Key Pathophysiological Feature of Metabolic Syndrome. Mediators of Inflammation, 2013, 2013, 1-2.	3.0	10
156	The liver and the kidney: two critical organs influencing the atherothrombotic risk in metabolic syndrome. Thrombosis and Haemostasis, 2013, 110, 940-958.	3.4	20
157	The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. European Heart Journal, 2012, 33, 846-856.	2.2	81
158	Update on the Role of Cannabinoid Receptors after Ischemic Stroke. Mediators of Inflammation, 2012, 2012, 1-8.	3.0	34
159	Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. European Heart Journal, 2011, 32, 1369-1378.	2.2	123
160	Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. European Heart Journal, 2011, 32, 412-421.	2.2	110
161	Systemic and Intraplaque Mediators of Inflammation Are Increased in Patients Symptomatic for Ischemic Stroke. Stroke, 2010, 41, 1394-1404.	2.0	106
162	CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. Journal of Molecular and Cellular Cardiology, 2009, 46, 612-620.	1.9	153

#	Article	IF	Citations
163	Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis, 2009, 205, 433-441.	0.8	67
164	CB$_2$ cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1145-H1155.	3.2	127
165	Ccr5 But Not Ccr1 Deficiency Reduces Development of Diet-Induced Atherosclerosis in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 373-379.	2.4	254
166	Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis. Future Cardiology, 2006, 2, 49-53.	1.2	9
167	New anti-inflammatory agents to reduce atherosclerosis. Archives of Physiology and Biochemistry, 2006, 112, 130-137.	2.1	3
168	Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature, 2005, 434, 782-786.	27.8	403
169	Toward a Role for Statins in Immunomodulation. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2002, 2, 478-480.	3.4	22